Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Inclusion Criteria:

• Sample collection or biopsy of tumor is clinically indicated as part of SOC
• Prior to preceding onto therapy for treatment

Exclusion Criteria:

• Unable to obtain sufficient sample